-
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
NCT07018713 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Centerville, Cincinnati, Cleveland
-
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Centerville, Cincinnati, Cleveland
-
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07674654 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Columbus, Milford, West Chester
-
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675 ·
Phase: Phase 3 ·
Ages: 12 Years to 17 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· Ohio: Akron, Cincinnati
-
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
NCT05897320 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· Ohio: Akron, Cincinnati
-
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· Ohio: Cincinnati, West Chester
-
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Ohio: Cincinnati, Dayton, New Albany
-
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07645924 ·
Phase: Phase 3 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Ohio: Columbus, Milford, West Chester
-
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466 ·
Phase: Phase 3 ·
Ages: 18 Years to 45 Years ·
Sex: Female
· Ohio: Centerville
-
BE WELL With Migraine: Brain Education and WELLness With Migraine
NCT05987592 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
NCT06972056 ·
Phase: Phase 4 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Ohio: Columbus
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· Ohio: Cincinnati, Cleveland, Dayton
-
Mind Body Balance for Pediatric Migraine
NCT04715685 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Overlapping Pain Trajectory Study
NCT05752396 ·
Phase: Not specified ·
Ages: 10 Years to 19 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
NCT04748601 ·
Phase: Phase 4 ·
Ages: 6 Years to 11 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· Ohio: Akron, Cincinnati, Cleveland, Columbus
-
Responding With Evidence and Access for Childhood Headaches
NCT05889624 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· Ohio: Cincinnati, Columbus
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
NCT05125302 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· Ohio: Cincinnati, Columbus, West Chester
-
Supraspinal Processing of Sensory Aspects of Pain
NCT05814497 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· Ohio: Cincinnati